This expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants, and additional announcements on new models and capabilities at its UK facilities
Working at the forefront of SCLC research, Crown Bioscience developed the HuPrime® and PDXact™ Jumpstart collections of SCLC models, which are the most comprehensive collection of commercially avai...
Using clinically-relevant models, Crown Bioscience helps researchers make the best decisions to speed the optimum drug candidates to clinical development.
Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryo...